X

Drug Profile

MG D 2020

Alternative Names: Meta-1 regulating therapy - Metagone Biotech; MG-D-2020

Latest Information Update: 31 Jan 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Metagone Biotech
Class Antineoplastics
Mechanism of Action Gene modulators; Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Cancer metastases

Most Recent Events

31 Jan 2022 Preclinical trials in Cancer metastases in Taiwan (unspecified route) (Metagone Biotech pipeline, January 2022)
05 Feb 2021 Metagone Biotech plans to submit IND application for Cancer metastases (Metagone Biotech pipeline, February 2021)
05 Feb 2021 Metagone Biotech plans preclinical development for Cancer Metastases (Metagone Biotech pipeline, February 2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com